Page 137 - 202011

CYP、ABC等基因的多态性研究，并综合考虑经济因素， irinotecan[J]. Cancer Sci，2018，109（12）：3934-3942.
合理建议患者进行 UGT1A1*6、*28 和 SLCO1B1 基因 [14] LI M，ZHANG XF，SUN G，et al. Co-administration risk
388A＞G、521T＞C 位点的联合检测，以降低患者用药 between regorafenib and irinotecan during the therapy of
风险、优化其个体化治疗方案。 lung cancer patients[J]. Latin Am J Pharm，2017，36（9）：
参考文献 1796-1800.
[15] YANG Y，ZHOU M，HU M，et al. UGT1A1*6 and
[ 1 ] 王秉阳，黄筱.每年新发癌症病例380万 防癌控癌我们还
UGT1A1*28 polymorphisms are correlated with irinote-
能做什么[N].科技日报，2019-08-29（07）.
can-induced toxicity：a meta-analysis[J]. Asia Pac J Clin
[ 2 ] BAILLY C. Irinotecan：25 years of cancer treatment[J]. Ph-
Oncol，2018，14（5）：e479-e489.
armacol Res，2019. DOI：10.1016/j.phrs.2019.104398.
[16] ZHANG X，YIN JF，ZHANG J，et al. UGT1A1*6 poly-
[ 3 ] DI PAOLO A，BOCCI G，POLILLO M，et al. Pharmacoki-
morphisms are correlated with irinotecan-induced neutro-
netic and pharmacogenetic predictive markers of irinote-
penia：a systematic review and meta-analysis[J]. Cancer
can activity and toxicity[J]. Curr Drug Metab，2011，12
Chemother Pharmacol，2017，80（1）：135-149.
（10）：932-943.
[17] CHEN X，LIU L，GUO Z，et al. UGT1A1 polymorphisms
[ 4 ] PAULIK A，NEKVINDOVÁ J，FILIP PS. Irinotecan toxic-
with irinotecan-induced toxicities and treatment outcome
ity during treatment of metastatic colorectal cancer：focus
in Asians with lung cancer：a meta-analysis[J]. Cancer
on pharmacogenomics and personalized medicine[J]. Tu-
Chemother Pharmacol，2017，79（6）：1109-1117.
mori，2018. DOI：10.1177/0300891618811283.
[18] HIKINO K，OZEKI T，KOIDO M，et al. Comparison of ef-
[ 5 ] HAHN RZ，ANTUNES MV，VERZA SG，et al. Pharmaco-
fects of UGT1A1*6 and UGT1A1*28 on irinotecan-in-
kinetic and pharmacogenetic markers of irinotecan toxicity
duced adverse reactions in the Japanese population：analy-
[J]. Curr Med Chem，2019，26（12）：2085-2107.
sis of the BioBank Japan Project[J]. J Hum Genet，2019，
[ 6 ] 金蕾，杨丽杰，陈岩，等.尿苷二磷酸葡萄糖醛酸转移酶基
64（12）：1195-1202.
因多态性对药物代谢影响的研究进展[J].中国药师，
[19] DIAS MM，MCKINNON RA，SORICH MJ. Impact of the
2013，16（1）：33-36. UGT1A1*28 allele on response to irinotecan：a systematic
[ 7 ] PAULIK A，GRIM J，FILIP S. Predictors of irinotecan tox-
review and meta-analysis[J]. Pharmacogenomics，2012，13
icity and efficacy in treatment of metastatic colorectal can- （8）：889-899.
cer[J]. Acta Medica：Hradec Kralove，2012，55（4）：153-
[20] LIU X，CHENG D，KUANG Q，et al. Association be-
159. tween UGT1A1*28 polymorphisms and clinical outcomes
[ 8 ] NEGORO Y，YANO R，YOSHIMURA M，et al. Influence of irinotecan-based chemotherapies in colorectal cancer：a
of UGT1A1 polymorphism on etoposide plus platinum-in- meta-analysis in Caucasians[J]. PLoS One，2013. DOI：
duced neutropenia in Japanese patients with small-cell 10.1371/journal.pone.0058489.
lung cancer[J]. Int J Clin Oncol，2019，24（3）：256-261. [21] WANG Y，SHEN L，XU N，et al. UGT1A1 predicts out-
[ 9 ] WANG XF，MA C，GONG FF，et al. Relationship between come in colorectal cancer treated with irinotecan and fluo-
UGT1A1 gene polymorphisms and irinotecan-induced se- rouracil[J]. World J Gastroenterol，2012，18（45）：6635-
vere adverse events[J]. Zhonghua Zhongliu Zazhi，2018， 6644.
40（8）：594-599. [22] BAI Y，WU HW，MA X，et al. Relationship between
[10] PENG H，DUAN Z，PAN D，et al. UGT1A1 gene poly- UGT1A1*6/*28 gene polymorphisms and the efficacy
morphism predicts irinotecan-induced severe neutropenia and toxicity of irinotecan-based chemotherapy[J]. Onco
and diarrhea in Chinese cancer patients[J]. Clin Lab， Targets Ther，2017. DOI：10.2147/OTT.S137644.
2017，63（9）：1339-1346. [23] LIU XH，LU J，DUAN W，et al. Predictive value of
[11] 王拥军，赵志刚.精准医疗与药物治疗个体化实操手册 UGT1A1*28 polymorphism in irinotecan-based chemo-
[M].北京：北京科学技术出版社，2017：379-385. therapy[J]. J Cancer，2017，8（4）：691-703.
[12] DE MAN FM，GOEY AKL，VAN SCHAIK RHN，et al. [24] TAKAHARA N，NAKAI Y，ISAYAMA H，et al. Uridine
Individualization of irinotecan treatment：a review of phar- diphosphate glucuronosyl transferase 1 family polypep-
macokinetics，pharmacodynamics，and pharmacogenetics tide A1 gene（UGT1A1）polymorphisms are associated
[J]. Clin Pharmacokinet，2018，57（10）：1229-1254. with toxicity and efficacy in irinotecan monotherapy for
[13] KIMURA K，YAMANO T，IGETA M，et al. UGT1A1 refractory pancreatic cancer[J]. Cancer Chemother Phar-
polymorphisms in rectal cancer associated with the effica- macol，2013，71（1）：85-92.
cy and toxicity of preoperative chemoradiotherapy using [25] 胡艳玲，史爱欣，傅得兴，等.基因多态性影响伊立替康疗

中国药房 2020年第31卷第11期 China Pharmacy 2020 Vol. 31 No. 11 ·1407 ·